Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., Budapest, 1093, Hungary,
Eur J Health Econ. 2014 May;15 Suppl 1:S35-43. doi: 10.1007/s10198-014-0592-6. Epub 2014 May 16.
Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug uptake. The objective of this paper was to provide an overview of biological treatment in six selected Central and Eastern European (CEE) countries, namely in the Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia. The literature is summarized with regard to the epidemiology, disease burden and use of biological agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Moreover, an estimate is provided on the prevalence and number of patients with biological treatment based on international and local sources. In view of the limited availability of information and uncertainty in data, there is an urgent need for development of systematic and comprehensive data collection in inflammatory rheumatic diseases in CEE countries.
生物药物彻底改变了炎症性风湿性疾病的治疗方法。在欧洲，治疗的可及性存在很大差异。一个国家的经济水平以及行政限制已被证明是决定生物药物使用的因素。本文的目的是概述六个选定的中东欧（CEE）国家（保加利亚、捷克共和国、匈牙利、波兰、罗马尼亚和斯洛伐克）的生物治疗情况。本文总结了类风湿关节炎、银屑病关节炎和强直性脊柱炎的流行病学、疾病负担和生物制剂使用情况。此外，还根据国际和本地资料，对生物治疗的患病率和患者人数进行了估计。鉴于信息有限且数据不确定，中东欧国家迫切需要制定炎症性风湿性疾病的系统和全面的数据收集。
